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Abstract
Background: It seems that lumen-apposing metal stents (LAMS) are displacing plastic stents in the therapy of
pancreatic-fluid collection in walled-off necrosis (WON). To date, there is no quality of evidence to recommend
LAMS as the standard treatment in the management of WON. The theoretical benefit of LAMS over plastic stents
needs to be proven.
Methods/design: This is a randomized controlled, multicenter, prospective clinical trial with two parallel groups,
without masking. One-hundred and fourteen patients with WON will undergo endoscopic ultrasound (EUS)-guided
transmural draining in nine tertiary hospitals in Spain and will be randomized to the LAMS or plastic-stent group.
The primary endpoint is the short-term (4 weeks) clinical success determined by the reduction of the collection (to
< 50% or < 5 cm in size), along with clinical improvement. Secondary endpoints: long-term (4 months) clinical
success (total resolution or 5 cm), procedure duration, level of difficulty, safety, and recurrences.
Discussion: The PROMETHEUS trial has been designed to determine whether LAMS are superior to plastic stents in
EUS-guided transmural drainage of WON.
Trial registration: ClinicalTrials.gov, ID: NCT03100578. Registered on 4 April 2017. https://clinicaltrials.gov/ct2/home
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Background
The Atlanta classification of pancreatic-fluid collection es-
tablishes that walled-off necrosis (WON) consists of a
variable amount of necrotic tissue within a reactive-tissue
wall. This derives from the encapsulation of acute necrotic
collections. Imaging tests reveal a well-defined wall sur-
rounding the collection, the formation of which typically
occurs at about 4 week from the origin of the acute or
chronic pancreatitis. The presence of more necrosis
worsens the prognosis; mortality in patients with necrotiz-
ing pancreatitis is as high as 15%, and it can reach 30% in
patients with infected necrosis [1, 2]. In case of symptom-
atic WON, drainage is considered, and in the last two de-
cades minimally invasive approaches (surgical or
endoscopic) have enjoyed increased acceptance in the
management of necrotic collections over open surgical
necrosectomy, with fewer adverse events (AEs) and less
long-term morbidity. Recent trials have shown that endo-
scopic approaches offer better clinical outcomes, with im-
provement in quality of life and lower costs [3–6].
In the last few decade, endoscopic techniques, such as
the use of endoscopic ultrasound-guided transmural
drainage, have been increasingly used as a first-line option
for the treatment of symptomatic WON [5, 7]. To date,
plastic stents (such as double plastic stents) have been be-
come the mainstay of endoscopic therapy for WON, until
the introduction of lumen-apposing metal stents (LAMS)
[8–10]. There is the hypothesis that the large diameter of
LAMS improves the drainage of WON with respect to
plastic stents (7–10 Fr) and carries less time-consuming
interventions, with a smaller number of endoscopic proce-
dures to achieve final success. Regarding safety, the risk of
leakage, perforation, or migration would theoretically be
reduced using the specific stent design of LAMS. However,
LAMS are more expensive, and their safety is controver-
sial, with a significantly higher rate of AEs, such as bleed-
ing, compared with plastic stents [11–14] (Table 1).
Although some international systematic endoscopic re-
views and meta-analyses have recommended LAMS as the
care standard for WON drainage, the quality of evidence
is not high (retrospective, registry-based, or non-
comparative) that LAMS are superior to PLASTIC stents
in the management of WON by EUS-guided transmural
drainage, and few studies have compared LAMS and plas-
tic stents [15–20]. For all these reasons, a multicenter,
prospective, parallel-group, randomized controlled clinical
trial was designed to assess whether LAMS are superior to
plastic stents in the endoscopic treatment of WON.
Methods/design
The PROMETHEUS trial is a randomized controlled, mul-
ticenter, prospective clinical trial with two parallel groups,
without masking and with a 1:1 allocation ratio. One hun-
dred and fourteen patients with WON will be scheduled
for endoscopic ultrasound (EUS)-guided transmural drain-
age in nine tertiary Spanish hospitals and will be random-
ized to the LAMS and plastic-stent groups. All the centers
are members of the Spanish Society of Digestive Endoscopy
(SEED), which acts as the promoter of this trial.
Central ethical approval of the study protocol has been
confirmed from the Comité Ético de Investigación Clín-
ica (CEIC) del Hospital Universitari de Bellvitge-
IDIBELL (ref approval no. 140/15) and we will not begin
recruiting at other centers in the trial until local ethical
approval has been obtained. A Standard Protocol Items:
Table 1 Comparative table of the two kinds of stents used in transmural drainage of pancreatic collections
Lumen-apposing metal stent Plastic
Advantages Disadvantages Advantages Disadvantages
Easy release Expensive Economical Smaller diameter
Wide diameter Less scientific evidence Easy extraction Shorter patency
Better drainage of solid waste and necrosis Temporary placement May be left permanently in place High occlusion rate
Direct necrosectomy via stent Traumatism caused by the ends Greater experience (studies) A single stent is not
enough for WON
Longer patency Not known whether permanent
placement is possible
High success rate (> 80–90%,
all types of collections)
Multiple > demanding
technique (MTGT for WOPN)
Correct visibility Worse visibility (fluoroscopy)
Short therapeutic time
Hemostatic effect
Prevents migration Leakage of liquid (in ostomy)
Anchoring effect
Prevents liquid leakage Migration
Easy extraction
MTGT Multiple transluminal gateway technique, WOPN Walled-off pancreatic necrosis
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Recommendations for Interventional Trials (SPIRIT)
Checklist is attached as Additional file 1.
Study population
This clinical trial will be performed at the endoscopy unit
of the digestive diseases departments of nine tertiary and
university centers in Spain. In order to participate in this
study, the patient must be a candidate for guided trans-
mural drainage with EUS of WON-type pancreatic collec-
tion as a local complication in acute pancreatitis. The
investigator at each center will be contacted to evaluate
the inclusion of the patient in the study. The patient will
be correctly informed by personnel knowledgeable about
the specifics of the study, who will help to resolve any
questions that may arise. The informed consent form will
be signed in the presence of participating personnel
knowledgeable about the study. The patient has the right
to opt out of the study at any time.
The inclusion and exclusion criteria are listed in Table 2.
Recruitment
Principal investigators from each center will have the
task of presenting strategies to promote enrollment and
to ensure the target sample size.
Randomization and masking
Patients will be enrolled in this trial by gastroenterolo-
gists, surgeons, and endoscopists who will evaluate the
cases in the inpatient wards or in the outpatient consult-
ation areas. The participants will be randomized with a
random-number table generated by an online platform.
A code list will be generated by randomization with a 1:1
randomization ratio, by blocks, stratified by centers and by
American Society of Anesthesiologists’ classification (ASA)
score. Each individual will be assigned a randomization code
along with the treatment that corresponds. Once the patient
meets the eligibility criteria and has provided informed con-
sent, we will proceed to the allocation of each participant cen-
trally, ensuring allocation concealment, and based on the
randomization list. To prevent different subject recruitment
rates at the various hospitals from interfering with the devel-
opment of the study, the entire population will be randomized
in blocks of four between the two treatment possibilities.
Procedural technique
Qualification of centers
The participation of a minimum of nine hospitals with an
inclusion of about 13–15 patients per year per hospital is
required. The investigators at the participating centers will
all have experience in endoscopic intervention and thera-
peutics, previous experience in EUS-guided transmural
drainage with metal and plastic stents (> 25 overall), and a
minimum of 10 procedures per year, in addition to appro-
priate material at their disposal for carrying out trans-
mural drainage with both types of stent.
General description of the technique
Each selected case will ensure a conclusive diagnostic revi-
sion with WON. In case of doubt, EUS-guided, fine-
needle aspiration will be considered prior to drainage to
rule out cystic tumor. Prophylactic antibiotic therapy will
be administered in accordance with the protocol of each
center. In case of INR > 1.5, this will be corrected in ac-
cordance with the protocol of each center until INR < 1.5.
Procedures will be performed under deep sedation in ac-
cordance with the directives of each center. In case of col-
lection > 10 cm (> 700mL), tracheal intubation by
anesthesiologist is recommended. Carbon dioxide insuffla-
tion is recommended, especially for endoscopic necrosect-
omy. The WON will be localized by using a linear
echoendoscope, selecting the appropriate optimal region
for carrying out the EUS-guided puncture. The collection
will be punctured with a 19-G needle (plastic or LAMS
group) or directly with an electrocauterizing device (free-
hand technique, only in the LAMS group). The guidewire
will be advanced and coiled into the WON cavity. Then,
the transmural ostomy will be carried out in accordance
with the normal procedure of the experienced
Table 2 Selection criteria for WON walled-off necrosis.
aDiagnosis of WON based on imaging procedures
Inclusion criteria:
Patients eligible for the trial must comply with all of the following at
randomization
• Age 18 years or older
• Patient with indication (ASGE, Jacobson BC, GIE2005) of drainage of
only one typea related to the symptomatology, as a local
complication of previous acute pancreatitis
• Patient capable of understanding and signing informed consent
form
• Patient understanding the type of study and complying with the
follow-up of complementary tests during the study’s duration
Exclusion criteria
• Pregnancy or breast-feeding
• Severe coagulation disorder: INR > 1.5 not correctible with
administration of plasma and/or platelets < 50,000/mm3
• Asymptomatic patients, without clinical indication of drainage,
except for those with vascular compression involvement
• Non-identification of solid content during EUS procedure
• Failure to sign informed consent form
• Patients with intellectual handicap who are unable to understand
the nature and possible consequences of the study, unless there is a
competent legal representative
• Patients unable to adhere to subsequent follow-up requirements
• Conditions that preclude upper digestive endoscopy, such as
stenosis
Note: If there are several pancreatic collections, this does not exclude the
patient from the trial. The patient is only excluded if there is more than one
symptomatic collection to be drained
EUS endoscopic ultrasound, INR international normalized ratio
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endoscopist. The use of a fluoroscope will be decided
upon on the basis of technical considerations and the
opinion of the endoscopic interventionist. The use (or
not) of a fluoroscope will be noted in the case report form
(CRF). The scale of the ostomy will be determined by the
size of the collection (see Table 3).
After the interventional procedure, all inpatients cases
will be returned to the hospital ward and will discharged
after clinical improvement. Outpatients will spend a
minimal of 24 h under observation and will be dis-
charged the next day unless there is no improvement of
symptoms or the appearance of AEs.
Plastic-stent group
Double-pigtail plastic stents (5–10 cm in length, diameter
7–8.5 10 French gauge (Fr), Advanix, Boston Scientific,
Spencer, USA) will be used. A minimum of one 10Fr pigtail
plastic stent will be placed. After initial EUS-guided access,
the ostomy will be dilated first, using a cystotome, and sec-
ondly with a balloon dilation. The plastic stent will be
inserted and delivered following the routine technique of
each interventional endoscopist. The number of the plastic
stent and size of the balloon used to dilate the ostomy will
depend on the WON size and content (see Table 3). The
time to plastic stent withdrawal will be considered until
total resolution by imaging. If there is pancreatic-duct in-
volvement, non-withdrawal of stent will be considered.
Metal group
The metal stents used in this study will be LAMS (10,
15, or 20 mm in diameter, and 10 mm in length,
HotAXIOS stent with an electrocautery-enhanced deliv-
ery system, Boston Scientific, Madrid, Spain). This is a
self-expanding metal stent totally covered with luminal
apposition. After the EUS-guided access into the WON
using first a 19-G or directly with the electrocautery tip,
the delivery system will be advanced into the cavity and
the distal flange will be deployed under EUS guidance.
Otherwise, the proximal flange will be released under
EUS or endoscopic guidance. The time to stent with-
drawal will depend on total resolution by imaging. How-
ever, there will be the intention to remove a LAMS no
later than 4–6 weeks.
Additional interventions
Necrosectomy will be considered in WON with predom-
inantly solid debris, using the technique at the discretion
of the endoscopist. In cases that require sessions of endo-
scopic necrosectomy, the different technical variants de-
scribed in the literature will be used (irrigation technique
with normal saline; mechanical technique using the com-
mon devices as snares, Dormia baskets or retrieval nets
for extraction of necrotic debris; or combined with naso-
cystic catheters). The periodicity will be every 2–5 days
depending on the decision of the expert endoscopist and
the clinical evolution of the patient.
Additional comments
In the event of technical failure in the placement of the
stent (plastic or LAMS) for any reason, alternative treat-
ment will be decided upon in accordance with the direc-
tives of the endoscopic interventionist, with the aim of
offering the patient the best possible solution.
The first controls will be on the first day following and at 4
weeks (see Table 4). If there is no short-term clinical success,
the most beneficial therapeutic approach for the patient will
be adopted in accordance with the criteria of the patient’s
medical team (for example: the use of technical variants at
initial drainage such as placement of coaxial plastic pigtail
within the LAMS, replacement or change the stent type, use
of nasocystic drainage or other known variants).
Every intervention, diagnostic procedure, and additional
therapeutic contribution will be noted in the CRF.
In the case of collections of significant size (i.e., 14 cm) with
clinical-radiological success but without the disappearance of
the collection (i.e., CTMD reduction from 14 to 6 cm), pre-
cluding the removal of the stent, a new CTMD will be per-
formed at 4weeks (8weeks) to assess removal of the stent.
Therefore, the removal of a stent is contemplated
when there is disappearance of the collection or a de-
crease < 5 cm.
Patients will remain in the hospital for a minimum of
24 h for clinical observation, under medical supervision.
Clinical evaluation and follow-up
Data collection
The collecting of clinical information on the patients will
begin at the outset (baseline) and will continue with
follow-up as established and defined in the study. AEs
will be noted from the beginning of the test until the
conclusion of follow-up by means of scheduled controls.
Calendar
The following time-points and data items will consti-
tute the data collection from the beginning through
successive controls: The collecting of data for pur-
poses of documentation will be carried out using a
CRF, which will serve as an easily accessed source of
Table 3 Number of stents along with technical variations
depending on size of WON, observed with EUS during
procedure
Type LAMS (n, ø) Plastic (n, ø)
WON < 10 cm 1, 10–15–20 mm ≥ 1, minimum 1 of 10Fr
(+ ostomy 8–10mm)
WON > 10 cm ≥ 1, > 15 mm ≥ 2, minimum 1 of 10Fr
(+ ostomy 10–15 mm)
LAMS lumen-apposing metal stent; WON walled-off necrosis, FR French
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information. After collection, the data will be intro-
duced into an electronic database by the participating
investigator of each center.
Follow-up
Patients will be assessed (visit, telephone call) on days 1 and
7, at 4, 8, and 16weeks, and at 6, 8, and 12months by
personnel participating in the study, with the aim of obtaining
information regarding signs and symptoms pointing to pos-
sible stent obstruction or migration, recurrence, or other AEs.
Any instances of death during the follow-up will be in-
vestigated to rule out any possible relation to the endo-
scopic procedure. Such occurrences will also be
recorded in the CRF.
If there is clinical suspicion of obstruction or migra-
tion of the stent, an upper endoscopy will be carried out.
Based on the findings of this procedure, the problem will
be resolved in accordance with the directives of the
intervening endoscopist. Any additional procedure or
endoscopic intervention will be duly documented.
Complications will be handled and treated in accordance
with the directives of the patient’s medical team. All add-
itional tests and interventions will be duly documented.
Definitions
The term WON is in accordance with the literature (lat-
est revision of Atlanta, Banks PA et al. Gut 2013) [1]. At
least two imaging tests will be required (CTMD, MRI,
EUS) prior to the transmural drainage, the results of
which must be in agreement on the classification of the
collection as WON.
Technical success is defined as the correct release of the
stent at both ends, with observed drainage of the liquid.
Clinical success is defined as the significant reduction
of the collection along with clinical resolution.
Recurrence is defined as a symptomatic pancreatic col-
lection diagnosed with imaging test during the follow-up
of prior procedure with initial clinical success.
AEs are defined as undesirable situations suffered by
patients during the study, whether related or not to the






































Blood test X X X X X
Imaging test X X X Xa X X
Symptomatology
X X X X X X X X X
Visit X X X X
Telephone
contact
X X X X







Medication X X X X X X X X X X
aOnly in case of radiological clinical success but with persistence of the collection > 5 cm
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EUS-guided transmural drainage with a stent (plastic or
metal). All AEs referred by patients or observed by the
medical team will be duly documented. All serious AEs
will be detailed, and the study promoter/principal inves-
tigator will be notified within 7 days. In the event of a
death, notification will be made within 24 h. AEs will be
recorded in both the clinical history of the patient and
the CRF, with appropriate medical terminology. When-
ever possible, the diagnosis rather than the symptoms
will be recorded. These guidelines are to be followed
from the time of the signing of informed consent until
30 days after the final visit in the study calendar. AEs will
be classified as mild, moderate, serious, or fatal, in accord-
ance with the nomenclature for AEs in endoscopy (ASGE
Workshops 2010, Cotton GIE 2010; 71:446–54). The de-
termination as to whether an AE is related to the EUS-
guided transmural drainage with stent (plastic or metal)
will be made by the patient’s medical team, the local inves-
tigator, and the principal investigator of the study.
In Additional file 2 is included information about AE
definitions and MEDDEV guidelines. “Research product
security surveillance” section, according to the definitions
set out in the MEDDEV 2.7/3 guidelines (rev 3, May
2015) “Guidelines on medical devices: Clinical investiga-
tions: Serious adverse event reporting under Directives
90/385/EECC and 93/42/EEC” (Additional file 2).
Outcomes
The primary outcome is the short-term (4 weeks) clinical
success (metal vs. plastic) determined by the reduction
of the collection (to < 50% or < 5 cm in size), along with
clinical improvement.
The secondary outcomes are long-term (4months)
clinical success (metal vs. plastic) determined by total
resolution or 5 cm, along with clinical improvement.
Technical: to assess the duration of the procedure and
the level of difficulty. Safety: to assess AE (early and
late). Hospital length of stay. Recurrences. Financial:
evaluate the relative costs of the two strategies.
Sample-size calculation
The sample-size calculation is based on the primary hy-
pothesis of detecting statistically significant differences
in the percentage of clinical success in the LAMS and
plastic-stents groups at 4 weeks after the intervention.
Published data suggest that the clinical success rate at 4
weeks in the LAMS group is expected to be 0.75 and in
the plastic-stent group it is expected to be 0.5. Fifty-
seven patients will be recruited in each group to reject
the null hypothesis that the proportion of clinical suc-
cess in the LAMS group is equal to that of the plastic
group with an 80% power. The type-I error associated
with this test will be 5%. To evaluate the hypothesis, the
chi-square test or Fisher’s exact test will be used de-
pending on of the application criteria. For the calcula-
tion, a planned interim analysis will be made for half of
the recruitment using O’Brien-Fleming’s type-I error ex-
pense function and a global loss rate of 5%. http://www.
stat.ubc.ca/~rollin/stats/ssize/b2.html
Statistical analysis
All study variables will be presented for stent groups and in
total, using descriptive statistics consistent with the nature
of the variable. The continuous variables will be described
indicating the number of non-missing observations, the
mean, the standard deviation, the minimum, the first quar-
tile, the median, the third quartile, and the maximum. Cat-
egorical variables will be described indicating the number
of non-missing observations and the percentages of the dif-
ferent categories by column.
Main analysis: main outcome is the percentage of pa-
tients’ radiological (morphological) success between
transmural drainage of the collection, measured at 4
weeks from intervention. The null hypothesis suggests
that there are no differences between the proportions of
the intervention group and the control group.
The level of statistical significance has been set at 5%.
To test the hypothesis, use the chi-square test or Fisher’s
exact test depending on the application criteria will be
used. To quantify the magnitude of the difference, the
relative risk of success will be estimated, in the metal-
stent group with respect to the plastic-stent group and
its confidence interval will be calculated at 95%.
Secondary variable analyses
To determine which factors are associated with clinical-
radiological success in the short term, a multivariate logis-
tic regression will be carried out. The variables of age and
sex, and factors predicting the location of the disease,
treatments received, size, and characteristics of the collec-
tion, previous ASA, etc. will be taken. In addition, the ap-
pearance of clinical recurrence will be considered by
means of an analysis of Kaplan-Meier survival. The factors
associated with clinical recurrence will be explored
through a multivariate Cox proportional risk model and
adjustment variables will also be taken.
Subgroup analysis
The main analysis will also be carried out in the follow-
ing subgroups:
ASA patients I–II vs. II–IV.
Data management
Throughout the study the promoters will monitor the
quality of the trial with special attention to protocol de-
viations and the quality of the data entered in the
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database. At the end of the trial, a meeting will be held
to consider the data management report. This report will
describe the different deviations from the protocol iden-
tified in each of the patients. These deviations will be
classified as major or minor, and those patients with
major deviations will be excluded from the protocol ana-
lysis. After the meeting, the suitability of the database
for analysis will be considered, and the database will
then be closed.
Statistical analysis plan
The statistical analysis plan will be finalized before the
close of the database. This plan will include all the ana-
lysis described and others, mainly on the sensitivity of
the results and the management of the missing data. In
the event that in the plan of statistical analysis there is
some deviation in the analysis of the main variable, an
addendum to the protocol will be made. No changes will
be made to the original analysis plan once the database
is closed.
Cost analysis
The procedure for determining the cost of the diagnostic
test is made up of several steps: calculation of the unit
cost, and accounting for all the costs associated with the
test, both direct and indirect.
Calculation process: observation of the performance
and accounting for all the factors involved in the proced-
ure (units, time, number of professionals involved).
Criteria to be considered: human resources, disposable
material, generic fungible supplies, pharmacy, laundry,
equipment, repairs/maintenance of equipment and facil-
ities, energy, cleaning, waste handling, rental, telephone




Depending on the initial endoscopic treatment carried
out, a cross-over rescue treatment may be considered
when the initial protocol treatment fails. For the plastic
treatment group ➔ metal stent (LAMS); for the metal
treatment group ➔ plastic stent. Another accepted res-
cue technique (only in cases of initial treatment failure)
in the branch of metal stent: insertion of coaxial plastic
pigtail within a LAMS.
In all these cases, the follow-up of the patients will be
maintained until the end of the study according to
protocol. Alternatively, if a cross-over treatment or tech-
nical variant is not possible, percutaneous surgical or
radiological treatment will be offered.
Withdrawal
Any AE or other clinical condition of the patient which,
at the clinician’s discretion, warrants withdrawal of the
patient from the study; pregnancy; or expressed wishes
of the patient. Withdrawal from treatment will not mean
suspension of the study, given that follow-up will be
maintained until the end of the study in accordance with
the protocol.
The need for surgical intervention for: in these cases,
patient follow-up will be ended.
Ethical aspects and confidentiality
The protocol will be approved by the CEIC of each par-
ticipating hospital as well as that of the coordinating
center (HUB). The study researchers will carry out their
tasks in compliance with ethical principles of clinical re-
search established in the Declaration of Helsinki, and
with the norms of Good Clinical Practices. It is planned
to hire a policy to cover the concepts and compensations
according to current legislation (RD 1591/2009) that
regulates clinical investigation with healthcare products.
Before starting the clinical trial, it is planned to request
authorization of the Spanish Agency for Medicines and
Health Products (AEMPS) and the CEICs. Before inclu-
sion of the patient in the trial, a written informed con-
sent will be requested. In relation to the study data we
will follow the provisions of Organic Law 15/1999 of 13
December on “Protection of Personal Data.”
Publication of results
There is a commitment to publish the results of this
study in high-impact international journals, should the
results be of sufficient scientific interest. However, no
patient names will appear in any article, and no one,
with the exception of the researchers in this study and
the members of the Hospital Ethical Committees, will
have access to the data, in accordance with the Law on
the Protection of Data of a Personal Nature.
Discussion
Although open surgical necrosectomy has been the trad-
itional treatment of choice in patients with infected or
symptomatic pancreatic necrosis, other minimally invasive
techniques have been developed in recent years (endo-
scopic necrosectomy, guided radiological percutaneous
drainage, and retroperitoneal treatment) for treating col-
lections, so as to improve on the high morbidity and mor-
tality rates of traditional surgical treatment [3, 21–23].
At present, endoscopic transmural drainage plus endo-
scopic necrosectomy represents a viable technique that
is reasonably safe and effective when carried out in cen-
ters that have experience in doing so. Although each of
these is a minimally invasive endoscopic technique, they
are not entirely free of complications, the most common
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of which are bleeding, perforation, post-procedural in-
fection, and stent migration [7, 24]. Additionally, with
the continuous technological advances being made and
the appearance of new materials for endoscopic use,
doubts have arisen as to which devices are best to use.
One clear example of this uncertainty is the choice of
stent. To date, most published studies on guided trans-
mural drainage with endoscopy have involved double
pigtail plastic stents, with the number and diameter
varying depending on the collection type [23, 24]. In the
past years, some reports have been published on the use
of self-expanding covered metal stents offering greater
diameter, and therefore greater volume in the drainage
of the collection [25–27]. However, both types of stent
are intended for bile drainage and are not expressly de-
signed for transmural drainage of abdominal collections,
so more dedicated stents were investigated [8].
Recently, LAMS designed for the drainage of pancreatic
collections have appeared with demonstrated efficacy in a
number of studies but they are also more costly [16–20].
These stents are totally covered and offer a maximum cali-
ber of 15–20mm, thereby allowing for endoscopic necro-
sectomy in repeated sessions without the need for
replacement. In our experience, they permit transmural
drainage of pancreatic collections and endoscopic necro-
sectomy if it is needed, they are safe and effective, and they
reduce the duration of the procedure [10, 28].
However, with the increasing use of these stents, sig-
nificant LAMS-related AEs (i.e., severe delayed bleeding,
buried stent syndrome, obstruction, migration) have
been reported in several papers.
To date there is only one comparative prospective
study of self-expanding LAMS type metal stents, versus
plastic stents in the endoscopic treatment of WON-type
pancreatic collections, and it concluded that there were
no significant differences in treatment outcomes be-
tween the two. In order to minimize LAMS-related AEs,
they recommend follow-up imaging and LAMS removal
at 3 weeks if collection is resolved [29].
The PROMETHEUS trial is supported by the Spanish
Society of Digestive Endoscopy and includes nine tertiary
centers, as well as experts in the management of WON.
Hospital Universitari de Bellvitge has the leadership and
main role in centralizing the decisions in case of doubts
and controversies, and in limiting heterogeneity.
In conclusion, this randomized multicenter trial is ne-
cessary and essential in the effort to clarify the safety
and theoretical superiority of LAMS in the management
of WON, compared with plastic stents.
Trial status
Protocol of submitted version, number and date: number
2.1; date June 2018
Recruitment: Start date 27 June 2017 and recruitment
will be completed by June 2020
Revision chronology:
a- PROMETHEUS, June 2017, original: version 1, first
draft of the study protocol.
b- PROMETHEUS, September 2017, amendment n° 1:
version 2.
 Main amendments: (1) to clarify the second
inclusion criterion – in case of more than one
collection, the EUS-guided drainage will be
limited to only one pancreatic collection (WON),
related to the symptomatology (Table 2); (2)
addition of the “Research product security
surveillance” section, according to the definitions
set out in the MEDDEV 2.7/3 guidelines (rev 3,
May 2015) “Guidelines on medical devices:
Clinical investigations: Serious Adverse event
reporting under Directives 90/385/EECC and 93/
42/EEC” (Additional file 2); (3) extension to nine
centers with respect to the initial protocol (four
centers); (4) procedural technique, rescue
section: in case of failure, adding of the
possibility of a “Technical variant” in LAMS
group – an insertion of coaxial plastic pigtail
within the metal stent
 Additional changes: (1) addition of new and
relevant references; change of the grading of the
AE classification (immediate, early, and late); (2)
commercial name of each stent; (3) start delayed,
from the beginning of 2016 to June 2017; (4)
procedural technique section: additional
comments regarding when and how some
technical variants can be made; and technical
notes about necrosectomy technique; (5) data
management paragraph in the statistical section;
and (6) telephone call at 7 days, and additional
new legend explaining the possibility of a second
imaging procedure at 8 weeks, only in case of
radiological clinical success but with persistence
of the collection > 5 cm (Table 4, Timeline)
c- PROMETHEUS, June 2018, amendment n°2: version
2.1 – definitive
 Minor changes: addition of a new size of LAMS
(20 mm in diameter).
AEMPS and CEIC have been notified after every
amendment, with acceptance by each institution
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3988-x.
Additional file 1. Standard Protocol Items: Recommendations for
Interventional Trial (SPIRIT) Checklist.
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Additional file 2. Safety definitions adverse events (AEs).
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